Skip to Main Content

Paper Details

Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
7
2020
17q22, 17q22 locus, Akt, CDK1/2, Enzalutamide, Metastatic Castration-Resistant Prostate Cancer, PLK1, RNA, RNF43, SRSF1, chromosome 17q22, enzalutamide, genomes, genomic regions, mCRPC, mCRPC tumors, men, metastatic castration-resistant prostate cancer, patient, patients, protein-coding genes, transcriptomes, tumor, tumors
Author NameAffiliation
Eric LuKnight Cancer Institute, Oregon Health & Science University
Joshua UrrutiaKnight Cancer Institute, Oregon Health & Science University
Robert E ReiterInstitute of Urologic Oncology, University of California Los Angeles
Robert E ReiterJonsson Comprehensive Cancer Center, University of California Los Angeles
Matthew B RettigJonsson Comprehensive Cancer Center, University of California Los Angeles
Matthew B Rettig
Christopher P EvansUniversity of California Davis Comprehensive Cancer Center
Primo N LaraUniversity of California Davis Comprehensive Cancer Center
Martin E GleaveUniversity of British Columbia
Tomasz M BeerKnight Cancer Institute, Oregon Health & Science University
George V ThomasKnight Cancer Institute, Oregon Health & Science University
Jiaoti HuangDuke University School of Medicine
Rahul AggarwalUniversity of California San Francisco
David A QuigleyUniversity of California San Francisco
Adam FoyeUniversity of California San Francisco
Alana S WeinsteinUniversity of California Santa Cruz
Joshua M StuartUniversity of California Santa Cruz
Joshua M StuartUniversity of California Santa Cruz
Felix Y FengUniversity of California San Francisco
Eric J SmallUniversity of California San Francisco
Joshi J AlumkalKnight Cancer Institute, Oregon Health & Science University
Joshi J AlumkalUniversity of Michigan Rogel Cancer Center ann arbor
  • 1 - 22

Datasets

Release 1.2